Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer

237 ABSTRACT The translation of basic research into improved therapies for breast cancer patients requires relevant preclinical models that incorporate spontaneous metastasis. We have completed a functional and molecular characterisation of a new isogenic C57BL/6 mouse model of breast cancer metastasis, comparing and contrasting it with the established BALB/c 4T1 model. Metastatic EO771.LMB tumours were derived from poorly metastatic parental EO771 mammary tumours. Functional differences were evaluated using both in vitro assays and spontaneous metastasis assays in mice. Results were compared to non-metastatic 67NR and metastatic 4T1.2 tumours of the 4T1 model. Protein and transcript levels of markers of human breast cancer molecular subtypes were measured in the four tumour lines, as well as p53 (Tp53) tumour-suppressor gene status and responses to tamoxifen in vivo and in vitro. Array-based expression profiling of whole tumours identified genes and pathways that were deregulated in metastatic tumours. EO771.LMB cells metastasised spontaneously to lung in C57BL/6 mice and displayed increased invasive capacity compared with parental EO771. By immunohistochemical assessment, EO771 and EO771.LMB were basal-like, as was the 4T1.2 tumour, whereas 67NR had a luminal phenotype. Primary tumours from all lines were negative for progesterone receptor, Erbb2/Neu and cytokeratin 5/6, but positive for epidermal growth factor receptor (EGFR). Only 67NR displayed nuclear estrogen receptor alpha (ERα) positivity. EO771 and EO771.LMB expressed mutant p53, whereas 67NR and 4T1.2 were p53-null. Integrated molecular analysis of both the EO771/EO771.LMB and 67NR/4T1.2 pairs RESEARCH ARTICLE

[1]  Robin L. Anderson,et al.  Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells , 2014, Growth factors.

[2]  Jason I. Herschkowitz,et al.  Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts , 2013, Genome Biology.

[3]  Martin Clynes,et al.  BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome , 2013, Breast Cancer Research.

[4]  Anita Grigoriadis,et al.  Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles , 2013, Modern Pathology.

[5]  E. Ziv,et al.  CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. , 2012, Cancer discovery.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[7]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[8]  P. Francis,et al.  Strategies for the discovery and development of therapies for metastatic breast cancer , 2012, Nature Reviews Drug Discovery.

[9]  J. Sleeman,et al.  Building the niche: the role of the S100 proteins in metastatic growth. , 2012, Seminars in cancer biology.

[10]  M. Bissell,et al.  The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin , 2012, Breast Cancer Research and Treatment.

[11]  M. Shackleton,et al.  Physiological Levels of Pik3ca H1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors , 2012, PloS one.

[12]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[13]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[14]  C. Lynch,et al.  Abstract 2464: Novel MMP-3 generated PTHrP peptides promote osteoblast proliferation: Implications for prostate to bone metastases , 2012 .

[15]  Mads Thomassen,et al.  Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers , 2012, Breast Cancer Research.

[16]  Robin L. Anderson,et al.  Integrin‐dependent response to laminin‐511 regulates breast tumor cell invasion and metastasis , 2012, International journal of cancer.

[17]  V. Pankratz,et al.  Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers , 2012, Breast Cancer Research.

[18]  Michael Jones,et al.  Genome-wide association analysis identifies three new breast cancer susceptibility loci , 2012, Nature Genetics.

[19]  K. Hunter,et al.  Mouse models of cancer: does the strain matter? , 2012, Nature Reviews Cancer.

[20]  W. Muller,et al.  PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. , 2011, The Journal of clinical investigation.

[21]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[22]  R. Schiff,et al.  Cytoplasmic Estrogen Receptor in Breast Cancer , 2011, Clinical Cancer Research.

[23]  J. Hicks,et al.  Insight into the heterogeneity of breast cancer through next-generation sequencing. , 2011, The Journal of clinical investigation.

[24]  Mitch Dowsett,et al.  Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. , 2011, Journal of the National Cancer Institute. Monographs.

[25]  Robin L. Anderson,et al.  Laminin α5-derived peptides modulate the properties of metastatic breast tumour cells , 2011, Clinical & Experimental Metastasis.

[26]  M. Febbraio,et al.  Myeloid-specific estrogen receptor α deficiency impairs metabolic homeostasis and accelerates atherosclerotic lesion development , 2011, Proceedings of the National Academy of Sciences.

[27]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[28]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[29]  M. Dowsett,et al.  Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer , 2011, Clinical Cancer Research.

[30]  R. Hicks,et al.  Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration , 2011, The Journal of Nuclear Medicine.

[31]  J. Watkinson,et al.  Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1 , 2010, BMC Medical Genomics.

[32]  Thomas Hawighorst,et al.  CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo , 2010, Breast Cancer Research and Treatment.

[33]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[34]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[35]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[36]  C. Eaves,et al.  Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. , 2010, Cancer research.

[37]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hubing Shi,et al.  Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. , 2009, Cancer research.

[39]  D. Foell,et al.  The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.

[40]  David M. Thomas,et al.  Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. , 2009, Cancer research.

[41]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[42]  Hiroyuki Aburatani,et al.  The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase , 2008, Nature Cell Biology.

[43]  A. Moon,et al.  Global Gene Expression Profiling Unveils S100A8/A9 as Candidate Markers in H-Ras-Mediated Human Breast Epithelial Cell Invasion , 2008, Molecular Cancer Research.

[44]  B. Fingleton,et al.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. , 2008, Cancer research.

[45]  Yasuhiro Ito,et al.  S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. , 2008, Current cancer drug targets.

[46]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[47]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[48]  S. Abrams,et al.  Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth1 , 2007, The Journal of Immunology.

[49]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[50]  E. Nice,et al.  Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. , 2007, The American journal of pathology.

[51]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[52]  G. Huper,et al.  Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. , 2007, Cancer research.

[53]  K. Hunter,et al.  Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models , 2007, Clinical Cancer Research.

[54]  R. Weinberg,et al.  Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. , 2007, Cancer research.

[55]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[56]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[57]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[58]  Robin L. Anderson,et al.  Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone , 2006, Breast Cancer Research.

[59]  J. Hopper,et al.  Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. , 2006, Cancer research.

[60]  Eytan Domany,et al.  Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer , 2005, Oncogene.

[61]  D. Albertson,et al.  Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2005, Nature.

[62]  C. Restall,et al.  Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. , 2005, Molecular cancer research : MCR.

[63]  A. Rustgi,et al.  β-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer , 2004, Oncogene.

[64]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[65]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[66]  A. Rustgi,et al.  ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. , 2004, Gene.

[67]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[68]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[69]  R. Matkowski,et al.  Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course , 2003, Virchows Archiv.

[70]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[71]  A. Wärri,et al.  Involvement of estrogen receptor β in terminal differentiation of mammary gland epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[72]  T. Nolan,et al.  Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  R. Anderson,et al.  Genes involved in breast cancer metastasis to bone , 2002, Cellular and Molecular Life Sciences CMLS.

[74]  D. Wilkinson.  Gene Expression Patterns , 2002, Brain Research.

[75]  R. Timpl,et al.  Recombinant human laminin-10 (alpha5beta1gamma1). Production, purification, and migration-promoting activity on vascular endothelial cells. , 2002, The Journal of biological chemistry.

[76]  B. Gusterson,et al.  Cell–matrix interactions during development and apoptosis of the mouse mammary gland in vivo , 2002, Developmental dynamics : an official publication of the American Association of Anatomists.

[77]  Arnold Neumaier,et al.  Introduction to Numerical Analysis , 2001 .

[78]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  F. Kittrell,et al.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. , 2000, The American journal of pathology.

[80]  N. Horseman,et al.  Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is induced by prolactin and suppressed by progesterone in mammary epithelium. , 2000, Endocrinology.

[81]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[82]  R. Anderson,et al.  Heat-induced Alterations in the Localization of HSP72 and HSP73 as Measured by Indirect Immunohistochemistry and Immunogold Electron Microscopy , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[83]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[84]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[85]  T. Martin,et al.  A novel orthotopic model of breast cancer metastasis to bone , 1999, Clinical & Experimental Metastasis.

[86]  K. Buetow,et al.  Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression , 1998, International journal of cancer.

[87]  L. K. Rasmussen,et al.  The primary structure of caprine PP3: amino acid sequence, phosphorylation, and glycosylation of component PP3 from the proteose-peptone fraction of caprine milk. , 1998, Journal of dairy science.

[88]  R. Mohammad,et al.  p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. , 1998, International journal of molecular medicine.

[89]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[90]  Z. Werb,et al.  Misregulation of Stromelysin-1 Expression in Mouse Mammary Tumor Cells Accompanies Acquisition of Stromelysin-1-dependent Invasive Properties* , 1997, The Journal of Biological Chemistry.

[91]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[92]  S. Gruber,et al.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[93]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[94]  B. Zetter,et al.  Adhesion molecules in tumor metastasis. , 1993, Seminars in cancer biology.

[95]  J. Spona,et al.  Immunohistochemical and Biochemical Measurement of Estrogen and Progesterone Receptors in Primary Breast Cancer Correlation of Histopathology and Prognostic Factors , 1993, Annals of surgery.

[96]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[97]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[98]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[99]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[100]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[101]  A. C. Carter,et al.  Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response , 1985, Cancer.

[102]  S. Rockwell,et al.  Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. , 1973, Radiation research.

[103]  G. L. Ross,et al.  Sustained Enhanced Growth of Carcinoma EO771 in C57 Black Mice , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[104]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[105]  H. B. Pearson,et al.  Investigating Metastasis Using In Vitro Platforms , 2013 .

[106]  Justine Wanjiku Mbugua.  Genes involved in Breast Cancer Metastasis , 2013 .

[107]  R. Kremer,et al.  Parathyroid hormone related protein (PTHrP) in tumor progression. , 2011, Advances in experimental medicine and biology.

[108]  Lodewyk F. A. Wessels,et al.  Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response , 2009, Breast Cancer Research and Treatment.

[109]  D. Albertson,et al.  Rac 1 b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability , 2009 .

[110]  N. Erin,et al.  Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. , 2008, International journal of molecular medicine.

[111]  M. Tomayko,et al.  Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.

[112]  Robin L. Anderson,et al.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits , 2004, Clinical & Experimental Metastasis.

[113]  M. Inaba,et al.  Significance of the parathyroid hormone-related protein expression in breast carcinoma , 2000, Breast cancer.

[114]  L. Coussens,et al.  Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.

[115]  E. Bryant.  Area-under-the-curve analysis and other analysis strategies for repeated measures clinical trials , 1983 .